Redcare PHARMACY

Half-year *report*

30 June *2026*

Table of *contents.*

About Redcare Pharmacy. 2

Key Figures H1 2026. 3

Interim Management Report. 4

Introduction. 4
Overall assessment by the Managing Board. 4
Business model, Group structure and corporate governance. 5
Business development. 5
Risk management. 10
Subsequent events. 10
Forecast. 10

Responsibility statement from legal representatives. 11

Consolidated interim financial statements. 12

Consolidated statement of profit and loss. 12
Consolidated statement of comprehensive income. 13
Consolidated statement of financial position. 14
Consolidated statement of cash flows. 15
Consolidated statement of changes in shareholders' equity. 16
Notes to the consolidated interim financial statements. 17

Definitions. 25

Contact. 27

About this *report.*

A definition or explanation of abbreviations and other terms used throughout this report can be found in the Definitions section. In some instances, numbers have been rounded for reader convenience. In this report, the name "Redcare" is sometimes used for convenience in contexts where reference is made to Redcare Pharmacy N.V. and / or any of its subsidiaries, as the context may require.

Forward-looking statements.
This document includes forward-looking statements derived from management's estimates, valid as of the time of preparation. Such statements pertain to future periods and are typically identified by terms such as "expect", "forecast", "predict", "intend", "plan", "estimate", "assume" or "anticipate". These statements are subject to risks and uncertainties, many of which are beyond Redcare Pharmacy's control. As a result, actual outcomes may vary significantly from those projected.



About Redcare Pharmacy.

Originally founded in 2001, Redcare Pharmacy N.V. is with €2.9B revenues in 2025 the leading online pharmacy in Europe and active in seven countries (Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland).

Headquartered in the Netherlands, Redcare Pharmacy offers its over 14 million active customers more than 500,000 different healthcare related products. Besides OTC drugs, nutritional supplements, beauty and personal care products, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands, operating as a true one stop pharmacy.

As the pharmacy of the future, Redcare stands for comprehensive pharmaceutical services for its customers – with pharmaceutical safety always being the top priority.

Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and is part of the SDAX.

Key Figures H1 2026.

REVENUE IN H1:
€ 1.70 billion
(+19%)

REPEAT ORDERS:
90%

SITE VISITS IN H1:
329 million
(+12%)

GROSS MARGIN IN H1 AT
21.5%

PARCELS SENT IN H1:
MORE THAN
138,000
PARCELS A DAY

AVERAGE SHOPPING BASKET SIZE:
€ 68.15

ACTIVE CUSTOMERS:
14.7 million
(+1.2 MILLION YOY)

74
NPS (NET PROMOTER SCORE).

EBITDA (ADJ.) IN H1:
EUR 44.0
MILLION

Redcare
PHARMACY

Interim Management Report.

Introduction.

On 29 July 2026, we published our Statutory Interim Report for the six-month period ended 30 June 2026. This includes the Consolidated Interim Financial Statements prepared in accordance with IAS 34, "Interim Financial Reporting", as adopted by the European Union.

This Statutory Interim Report for the six-month period ended 30 June 2026, including the Consolidated Interim Financial Statements, has not been audited or reviewed by an external auditor.

Overall assessment by the Managing Board.

In the first half of 2026, Redcare Pharmacy continued its strong business development and achieved substantial growth in both revenue and profitability. Growth was driven in particular by the continued strong development of the German Rx business, while non-Rx growth continued to recover during the second quarter.

The Company also maintained strong growth across its other markets and reached an important milestone in the second quarter, when the International segment delivered positive EBITDA for the first time.

The active customer base expanded further during the reporting period, both year over year and quarter over quarter. Customer satisfaction remained high, underlining the strength of Redcare Pharmacy's customer proposition. Overall, the business performance in the first half of the year confirms the Company's strategic direction.

Based on the strong development in the first half of 2026, the Managing Board upgraded the full-year guidance in June and confirms this outlook.

Important events during the reporting period.

During the first quarter of 2026, Redcare Pharmacy completed the redemption of EUR 64.5 million of the 2021/2028 convertible bonds. Further information is provided in the section Notes to the consolidated financial statements.

At Redcare Pharmacy's Annual General Meeting on April 15, 2026, shareholders approved all agenda items with an absolute majority. This included the appointment of Hendrik Krampe as member of the Managing Board and Chief Financial Officer, as well as the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. Following these appointments, the Supervisory Board consists of Michael Köhler as Chair, Peter Schmid von Linstow as Vice-Chair, Stephan Weber, Anja Hendel and Max Müller.

On April 28, 2026, Redcare Pharmacy announced that Dirk Brüse, Chief Commercial Officer, is stepping down from the Managing Board for personal reasons.

On June 15, 2026, Redcare Pharmacy upgraded its financial guidance for the full year 2026 following the strong business development in the first half of the year. The Company now expects total revenue growth of 15% to 17%, Group non-Rx revenue growth of 10% to 12%, Rx revenue in Germany of EUR 680 million to EUR 720 million and an adjusted EBITDA margin of 2.5% to 3.0%.

No other events occurred during the reporting period that had a material impact on the Group's business development, financial position or results of operations.

Overall economic situation.

In the first half of 2026, macroeconomic conditions in the euro area remained challenging. Annual inflation increased to 3.2% in May before easing to 2.8% in June, remaining above the European Central Bank's (ECB) medium-term target of 2%. Against this backdrop, the ECB raised its deposit facility rate by 25 basis points to 2.25% in June 2026.

Economic growth remained subdued. According to the European Commission's Spring 2026 Economic Forecast, GDP in the euro area is expected to grow by approximately 0.9% in 2026, while growth of around 0.6% is projected for Germany. Business sentiment in Germany improved slightly towards the end of the reporting period: the ifo Business Climate Index increased from 85.0 points in May to 85.6 points in June.

The gradual recovery of the German e-commerce sector continued during the first half of 2026. According to BEVH data, online sales of goods increased by approximately 4.3% year over year. Growth accelerated from 3.6% in the first quarter to 5.1% in the second quarter, despite the continued weakness of the broader consumer environment.

Within the pharmacy sector, online channels continued to develop more strongly than the overall e-commerce market. According to BEVH data, online sales of medicines in Germany increased by 9.8% in the first quarter and by 13.9% in the second quarter of 2026. According to BEVH, the second-quarter increase represented the strongest growth since the introduction of electronic prescriptions, indicating continued momentum in the online pharmacy market.

Business model, Group structure and corporate governance.

Business model and corporate governance remain unchanged to the annual report 2025. We have simplified the group structure by merging Europa Apotheek Venlo B.V. into Shop-Apotheke B.V. and Europa Apotheek Service Venlo B.V. into Shop-Apotheke Service B.V. with effective date January 1, 2026. Both mergers had no impact on the Group's results.

Business development.

Non-financial performance indicators.

As of June 30, 2026, Redcare Pharmacy's active customer base reached 14.7 million, up by around 0.5 million compared with the previous quarter and by 1.2 million year over year. Order volumes also increased compared with the prior-year period. The average basket value, excluding MediService and platform sales, continued its positive year-over-year development, rising to EUR 68.15 in H1 2026 from EUR 63.91 in H1 2025. This development was supported by the continued strong growth in Rx sales, which generate higher basket values. The return rate remained minimal at 0.7%.

	2024				2025				2026	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Site visits	126.7	125.6	121.7	135.9	151.8	141.5	138.4	150.4	167.5	161.3
Mobile visits	98.1	96.7	92.3	102.8	116.2	108.7	105.0	111.3	125.5	123.2
Mobile share	77 %	77 %	76 %	76 %	77 %	77 %	76 %	74 %	75 %	76 %
Number of orders (million)	8.9	8.7	8.8	10.1	11.5	10.5	10.3	11.1	12.6	12.3
Repeat orders	87 %	87 %	88 %	88 %	89 %	89 %	90 %	91 %	90 %	90 %
Return rate	0.8 %	0.7 %	0.8 %	0.6 %	0.7 %	0.7 %	0.7 %	0.7 %	0.7 %	0.7 %
Active customers (million)	11.2	11.6	11.9	12.5	13.1	13.5	13.7	13.9	14.2	14.7
Average basket size	€58.92	€59.68	€61.84	€63.16	€62.44	€65.59	€67.1	€69.1	€67.9	€68.37
Net promoter score (NPS)	69.8	68.4	69.0	67.5	63.9	64.4	72.2	73.5	75.0	74.0

Revenues and results of operations.

In the first half of 2026, Redcare Pharmacy N.V.'s total Group revenue increased by 19.4% year over year to EUR 1,703.0 million (H1 2025: EUR 1,426.5 million). This development was driven by continued strong Rx growth, particularly in Germany, while non-Rx growth continued to recover.

Gross profit at Group level increased by 9.1% to EUR 366.6 million in the first half of 2026, compared with EUR 336.0 million in the prior-year period. The gross profit margin amounted to 21.5%, compared with 23.6% in H1 2025. The year-over-year decline was mainly attributable to the higher share of Rx revenue, the impact of the Rx bonus introduced in Q3 2025 and a competitive non-Rx environment. The gross profit margin improved sequentially from 21.0% in Q1 2026 to 22.1% in Q2 2026, supported by improved demand and pricing conditions in non-Rx and the normalisation of temporary effects due to the delayed recognition of retail media revenue in the first quarter. Rx accounted for 38% of total revenue, up from 34% in the prior-year period.

Adjusted selling and distribution expenses amounted to EUR 279.3 million in H1 2026 (H1 2025: EUR 269.7 million), equivalent to 16.4% of revenue compared with 18.9% in the prior-year period. The improvement in the expense ratio was driven by more efficient marketing spending and fixed cost leverage. Adjusted administrative expenses increased to EUR 43.5 million (H1 2025: EUR 39.5 million), representing 2.6% of revenue compared with 2.8% in the prior-year period. The lower ratio reflects scale efficiencies as the business continued to expand.

Adjusted EBITDA increased by 62% to EUR 44.0 million, corresponding to a margin of 2.6% (H1 2025: EUR 27.2 million; 1.9%). Profitability improved sequentially during the reporting period, with the adjusted EBITDA margin rising from 1.7% in Q1 2026 to 3.5% in Q2 2026. Improvements in the selling and distribution and administrative expense ratios, together with the sequential recovery in the gross profit margin, more than offset the year-over-year margin decline.

Total depreciation and amortisation amounted to EUR 33.9 million (H1 2025: EUR 34.1 million). EBIT improved to EUR 8.6 million, compared with EUR -9.7 million in the prior-year period. On an adjusted basis, EBIT amounted to EUR 10.1 million.

Net finance costs and income taxes totalled EUR -15.5 million, compared with positive EUR 7.0 million in H1 2025. The prior-year figure included a one-off positive effect of EUR 14.2 million related to the partial repurchase of outstanding convertible bonds in April 2025. The net result for the first half of 2026 was EUR -6.9 million, compared with EUR -2.8 million in the prior-year period. The adjusted net result amounted to EUR -5.4 million.

Consolidated *revenues*
(in € million)



Consolidated *gross profit*
(in € million)



Segment performance.

DACH segment.

The DACH region – Redcare Pharmacy's largest segment by revenue, covering Germany, Austria and Switzerland – continued its strong growth trajectory in the first half of 2026, with momentum improving during the reporting period. Segment revenue increased by 20.1% year over year to EUR 1,389.1 million (H1 2025: EUR 1,156.5 million), driven by continued strong Rx growth and the recovery in non-Rx. Rx revenue across the DACH region increased by 34.9% to EUR 655.3 million (H1 2025: EUR 485.6 million), with Germany recording growth of 56.6% to EUR 347.5 million.

Gross profit in the DACH region increased by 9.1% to EUR 290.1 million (H1 2025: EUR 266.0 million). The gross margin amounted to 20.9%, compared with 23.0% in the prior-year period. Gross margin improved sequentially from 20.5% in Q1 2026 to 21.3% in Q2 2026, supported by improving non-Rx conditions, especially in Germany.

Adjusted EBITDA increased by 51.6% to EUR 46.1 million in H1 2026 (H1 2025: EUR 30.4 million), corresponding to a margin of 3.3% compared with 2.6% in the prior-year period. In Q2 2026, adjusted EBITDA increased to EUR 28.1 million from EUR 20.1 million in Q2 2025, with the margin improving to 4.0% from 3.5%.

International segment.

The International segment, comprising Redcare Pharmacy's activities in Belgium, France, Italy and the Netherlands, recorded continued double-digit revenue growth in the first half of 2026. Segment revenue increased by 16.2% year over year to EUR 313.8 million (H1 2025: EUR 270.0 million).

Gross profit in the International segment increased by 9.1% to EUR 76.4 million (H1 2025: EUR 70.1 million). The gross margin was 24.4%, compared with 26.0% in the prior-year period. Gross margin improved significantly during the reporting period, rising from 23.0% in Q1 2026 to 25.7% in Q2 2026 as temporary effects from the first quarter normalised.

Adjusted EBITDA improved to EUR -2.1 million in H1 2026 (H1 2025: EUR -3.2 million), corresponding to a margin of -0.7% compared with -1.2% in the prior-year period. In Q2 2026, the segment delivered positive adjusted EBITDA of EUR 1.4 million for the first time, compared with EUR -2.0 million in Q2 2025, corresponding to a margin of 0.9% versus -1.5%.

H1 2026 Segment development

in millions of Euros	DACH	International	Consolidated
Revenues	1,389.1	313.9	1,703.0
Gross Profit	290.1	76.5	366.6
EBITDA	45.1	-2.6	42.5
Adjusted EBITDA	46.0	-2.0	44.0

H1 2025 Segment development

in millions of Euros	DACH	International	Consolidated
Revenues	1,156.5	270.0	1,426.5
Gross Profit	266.0	70.0	336.0
EBITDA	28.6	-4.3	24.3
Adjusted EBITDA	30.4	-3.2	27.2

Q2 2026 Segment development

in millions of Euros	DACH	International	Consolidated
Revenues	695.6	157.9	853.5
Gross Profit	148.0	40.7	188.7
EBITDA	27.8	1.3	29.1
Adjusted EBITDA	28.0	1.5	29.5

Q2 2025 Segment development

in millions of Euros	DACH	International	Consolidated
Revenues	574.0	135.2	709.2
Gross Profit	133.8	34.9	168.7
EBITDA	19.1	-2.6	16.5
Adjusted EBITDA	20.1	-2.0	18.1

Cash flow.

Cash flow, including cash and short-term financial assets, in the period.

in millions of Euros	Unaudited 30 June 2026	Unaudited 30 June 2025
Cash and short-term financial assets at the beginning of the period	203.5	177.6
Net cash flow for/from operating result	39.0	25.0
Net cash flow for/from working capital	-5.7	45.0
Net cash flow for/from investing activities	-41.8	-57.1
Net cash flow for/from financing activities	-77.2	124.4
Effect of movements in exchange rates on cash held	-0.2	-0.2
Net increase/decrease in cash and short term financial asses	-85.9	137.1
Cash and short-term financial assets at the end of the period	117.6	314.7

Reconciliation of cash and short-term financial assets.

The cash flow presents the development of the total of cash and short-term financial assets. The overview below contains a reconciliation of the total cash and short-term financial assets to cash and cash equivalents in accordance with the Consolidated statement of cash flows.

The other short-term financial assets of EUR 42.6 million (31 December 2025: EUR 111.1 million) include fixed term deposits with a duration of one year.

in millions of Euros	Unaudited 30 June 2026	31 December 2025	Increase/(Decrease)
Cash and cash equivalents	76.3	92.4	-16.1
Amounts due to banks	-1.3	0.0	-1.3
Total cash and cash equivalents	75.0	92.4	-17.4
Other short term financial assets	42.6	111.1	-68.5
Total cash and short-term financial assets	117.6	203.5	-85.9

Operating cash flow amounted to a positive EUR 33.3 million in the first half of 2026, compared with EUR 70.0 million in the prior-year period. This resulted from an operating result adjusted for depreciation, amortisation and taxes of EUR 39.0 million, partly offset by negative working capital movements of EUR 5.7 million. The working capital development mainly reflected higher trade and other receivables, partly offset by movements in other net current assets and inventories.

Net cash used by investing activities amounted to EUR 41.8 million in H1 2026, compared with net cash used in investing activities of EUR 57.1 million in H1 2025. Investments in property, plant and equipment and intangible assets amounted to EUR 43.1 million in H1 2026, compared with EUR 57.2 million in H1 2025, and mainly related to ongoing capacity and efficiency initiatives.

Cash flow from financing activities amounted to EUR -77.2 million, compared with positive EUR 124.4 million in the prior-year period. The outflow was mainly driven by the redemption of convertible bonds of EUR 64.5 million. Further financing cash flows included interest paid, lease payments, the repayment of other long-term loans and a dividend payment to minority shareholders, partly offset by proceeds from exercised share options. In the prior-year period, financing cash flow was primarily influenced by proceeds from the issuance of convertible bonds.

Overall, cash and short-term financial assets decreased by EUR 85.9 million during the reporting period. Including exchange-rate effects, cash and cash equivalents as presented in the cash flow statement amounted to EUR 75.0 million at June 30, 2026, compared with EUR 92.4 million at the beginning of the year. The amount is presented net of amounts due to banks of EUR 1.3 million. The other short term financial assets amounted EUR 42.6 million at June 30, 2026 compared with EUR 111.1 million at the beginning of the year.

Assets and liabilities.

As of June 30, 2026, total assets amounted to EUR 1,154.6 million, compared with EUR 1,214.3 million at December 31, 2025. The decrease mainly reflected lower current assets, driven by the reduction in other financial assets and cash and cash equivalents. This was partly offset by higher trade and other receivables and continued investments in property, plant and equipment.

Non-current assets increased to EUR 604.6 million (December 31, 2025: EUR 594.9 million). Property, plant and equipment rose to EUR 139.3 million (December 31, 2025: EUR 119.9 million), reflecting continued investments in capacity and efficiency initiatives. Right-of-use assets decreased to EUR 67.1 million (December 31, 2025: EUR 70.8 million), while intangible assets amounted to EUR 387.5 million (December 31, 2025: EUR 393.5 million), mainly reflecting scheduled depreciation and amortisation.

Current assets decreased to EUR 550.0 million (December 31, 2025: EUR 619.4 million). Other financial assets declined to EUR 42.6 million (December 31, 2025: EUR 111.1 million), mainly reflecting a reduction in securities and fixed-term deposits during the reporting period. Cash and cash equivalents decreased to EUR 76.3 million (December 31, 2025: EUR 92.4 million). In the cash flow statement, cash and cash equivalents are presented net of amounts due to banks of EUR 1.3 million as of June 30, 2026. Accordingly, cash and cash equivalents as presented in the cash flow statement amounted to EUR 75.0 million. Trade and other receivables increased to EUR 152.8 million (December 31, 2025: EUR 129.5 million), while inventories remained broadly stable at EUR 213.3 million (December 31, 2025: EUR 214.0 million).

On the equity and liabilities side, total equity amounted to EUR 475.1 million (December 31, 2025: EUR 479.2 million). The development mainly reflected the net result for the reporting period and distributions to non-controlling interests. Despite the slight decline in absolute terms, the equity ratio increased to 41.2% from 39.5% at year-end 2025, reflecting the lower balance-sheet total.

Non-current liabilities decreased slightly to EUR 332.6 million (December 31, 2025: EUR 335.1 million). Loans and borrowings remained broadly stable at EUR 330.6 million, while deferred tax liabilities decreased to EUR 1.6 million from EUR 4.4 million.

Current liabilities decreased to EUR 346.9 million (December 31, 2025: EUR 400.0 million). Current loans and borrowings declined to EUR 22.8 million (December 31, 2025: EUR 86.3 million), mainly following the redemption of the remaining 2021/2028 convertible bonds during the first quarter. Trade and other payables were broadly stable at EUR 252.2 million (December 31, 2025: EUR 253.0 million). Other current liabilities increased to EUR 70.6 million from EUR 60.7 million, while amounts due to banks amounted to EUR 1.3 million.

Risk management.

The Group's risk management system, risk categories and principal risks that could have a material impact on its business model, financial position and results of operations are described in the Annual Report 2025, starting on page 118. These disclosures are deemed incorporated and repeated in this report by reference.

There have been no material changes to the Company's overall risk assessment during the reporting period. Redcare Pharmacy's business remains subject to regulatory and legal developments, particularly in relation to pharmaceutical e-commerce and the pharmacy and healthcare markets in which the Group operates. Such developments may have a favorable or unfavorable impact on its business model, financial position and results of operations.

Subsequent events.

No material events occurred after the balance sheet date.

Forecast.

Following the guidance upgrade announced on June 15, 2026, the Managing Board of Redcare Pharmacy expects the following for full year 2026:

- Total revenue growth of 15% to 17%.
- Rx revenue in Germany of EUR 680 million to EUR 720 million, representing growth of 35% to 43%.
- Total Group non-Rx revenue growth of 10% to 12%.
- Total Redcare adjusted EBITDA margin of 2.5% to 3.0%.

Responsibility statement from legal representatives.

Sevenum, the Netherlands, 28 July 2026

To the best of our knowledge and in accordance with the applicable reporting principles for half-year financial reporting, the half-year consolidated financial statements give a true and fair view of the Company's assets, liabilities, financial position and profitability, and the half-year management report of the Group includes a fair review of the development and performance of the business, including financial results. The position of the Company is described so that an accurate assessment of the current situation is conveyed, as well as a description of the principal opportunities and risks associated with the expected development of the Group for the remainder of the fiscal year.

Redcare Pharmacy N.V.

The Management Board

Olaf Heinrich Hendrik Krampe Theresa Holler Lode Fastré

Consolidated interim financial statements.

Consolidated statement of profit and loss.

in millions of Euros	Unaudited 30.06.2026	Unaudited 30.06.2025
Revenue	1,703.0	1,426.5
Cost of sales	-1,336.4	-1,090.5
Gross profit	**366.6**	**336.0**
Other income	0.1	0.4
Selling and Distribution	-308.1	-298.7
Administrative Expense	-50.0	-47.4
Operating result	**8.6**	**-9.7**
Finance income	0.5	16.7
Finance expense	-14.7	-15.6
Share of profit of associates and joint ventures	0.7	0.3
Result before tax	**-4.9**	**-8.3**
Income tax	-2.0	5.5
Result after tax	**-6.9**	**-2.8**
Attributable to:		
Owners of Redcare Pharmacy N.V.	-5.8	-1.5
Non-controlling interests	-1.1	-1.3
	-6.9	-2.8
Earnings per share	EUR	EUR
Basic earnings per share	-0.29	-0.07
Diluted earnings per share	-0.29	-0.07

Consolidated statement of comprehensive income.

in mio. EUR	Unaudited 30.06.2026	Unaudited 30.06.2025
Result for the period	**-6.9**	**-2.8**
Other comprehensive income		
Items that are or may be reclassified subsequently to profit or loss		
- Foreign operations - foreign currency translation differences	0.2	-0.1
Items that will not be reclassified to profit or loss		
- Remeasurement of net defined benefit plans	0.0	0.8
- Income taxes from remeasurement of net defined benefit plans	0.0	-0.1
Other comprehensive income/loss for the period	**0.2**	**0.6**
Total comprehensive result	**-6.7**	**-2.2**
Total comprehensive result attributable to:		
Owners of Redcare Pharmacy N.V.	-5.7	-1.2
Non-controlling interests	-1.0	-1.0
	-6.7	**-2.2**

Consolidated statement of financial position.

in millions of Euros	Unaudited 30.06.2026	31.12.2025
Assets		
Non-current assets		
Property, plant and equipment	139.3	119.9
Right of use assets	67.1	70.8
Intangible assets	387.5	393.5
Deferred tax assets	1.6	1.6
Other financial assets	7.6	7.6
Investments in joint ventures	1.5	1.5
	604.6	**594.9**
Current assets		
Inventories	213.3	214.0
Trade and other receivables	152.8	129.5
Prepayments and other current assets	65.0	72.4
Other financial assets	42.6	111.1
Cash and cash equivalents	76.3	92.4
	550.0	**619.4**
Total assets	**1,154.6**	**1,214.3**
Equity and liabilities		
Shareholders' equity		
Issued capital and share premium	759.2	755.9
Reserves / accumulated losses	-301.9	-296.7
Equity attributable to owners of the Company	**457.3**	**459.2**
Non-controlling interests	17.8	20.0
Total equity	**475.1**	**479.2**
Non-current liabilities		
Loans and Borrowings	330.6	330.3
Employee benefit liabilities	0.4	0.4
Deferred tax liability	1.6	4.4
	332.6	**335.1**
Current liabilities		
Trade and other payables	252.2	253.0
Loans and Borrowings	22.8	86.3
Amounts due to banks	1.3	0.0
Other current liabilities	70.6	60.7
	346.9	**400.0**
Total equity and liabilities	**1,154.6**	**1,214.3**

Consolidated statement of cash flows.

in millions of Euros	Unaudited 30.06.2026	Unaudited 30.06.2025
Cash flow from operating activities		
Operating result	8.6	**-9.7**
Adjustments for:		
– Depreciation and amortisation of non-current assets	33.9	34.1
– Net foreign exchange differences	-0.2	0.3
– Share-based payment charge for the period	1.4	1.4
Corporate income tax paid	-4.7	-1.1
Operating result adjusted for depreciation and amortisation and taxes	39.0	25.0
Movements in:		
- (Increase)/decrease in trade and other receivables	-22.8	-8.9
- (Increase)/decrease in inventory	1.0	-7.9
- Increase/(decrease) in trade and other payables	-1.4	61.3
- Increase/(decrease) in other net current assets	17.5	0.5
Total change in working capital	-5.7	45.0
Net cash (used in)/generated by operating activities	**33.3**	**70.0**
Cash flow from investing activities		
Investment for property, plant and equipment	-25.8	-38.9
Investment for intangible assets	-17.3	-18.3
Investment in other financial assets	68.6	-142.6
Dividend received from associates	0.7	0.3
Interest received	0.5	2.1
Net cash (used in)/generated by investing activities	**26.7**	**-197.4**
Cash flow from financing activities		
Interest paid	-8.0	-5.2
Capital increase exercised options	2.4	0.4
Payment of dividend to minority shareholder	-1.3	-5.1
Repayment of other long-term loans	-0.8	-0.8
Proceeds from other long-term loans	0.0	0.0
Proceeds from convertible bond issuance	0.0	296.5
Early redemption of convertible bonds	-64.5	0.0
Cash-out lease payments	-5.0	-4.1
Net cash (used in)/generated by financing activities	**-77.2**	**124.4**
Net increase/(decrease) in cash and cash equivalents	**-17.2**	**-3.0**
Cash and cash equivalents at the beginning of the period	**92.4**	**96.9**
Effect of movements in exchange rates on cash held	-0.2	-0.2
Cash and cash equivalents at the end of the period	**75.0**	**93.7**

Consolidated statement of changes in shareholders' equity.

in millions of Euros	Equity attributable to Redcare Pharmacy shareholders								
	Share capital	Share premium	Retained earnings	Equity part on CB	Reserve for stock options	Translation Reserve	Equity	Non controlling interests	Total equity
Equity as of 1 January 2025	**0.4**	**754.9**	**-324.3**	**31.7**	**20.7**	**0.6**	**484.0**	**26.0**	**510.0**
Comprehensive income for the period									
Loss for the period	0.0	0.0	-1.5	0.0	0.0	0.0	-1.5	-1.3	-2.8
Other comprehensive income for the period	0.0	0.0	0.4	0.0	0.0	-0.1	0.3	0.3	0.6
Total comprehensive income for the period	**0.0**	**0.0**	**-1.1**	**0.0**	**0.0**	**-0.1**	**-1.2**	**-1.0**	**-2.2**
Capital increase	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital increase exercised options	0.0	0.5	0.0	0.0	-0.1	0.0	0.4	0.0	0.4
Share-based payment charge for the period	0.0	0.0	0.0	0.0	1.5	0.0	1.5	0.0	1.5
Dividend paid to non-controlling interests	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.2	-5.2
Issuance of convertible bonds	0.0	0.0	0.0	50.9	0.0	0.0	50.9	0.0	50.9
Repurchase of convertible bonds	0.0	0.0	-4.7	-22.2	0.0	0.0	-26.9	0.0	-26.9
Balance as at 30 June 2025 (unaudited)	**0.4**	**755.4**	**-330.1**	**60.4**	**22.1**	**0.5**	**508.7**	**19.8**	**0.0**
Comprehensive income for the period									
Loss for the period	0.0	0.0	-36.2	0.0	0.0	0.0	-36.2	-0.4	-36.6
Other comprehensive income for the period	0.0	0.0	0.6	0.0	0.0	0.1	0.7	0.6	1.3
Total comprehensive income for the period	**0.0**	**0.0**	**-35.6**	**0.0**	**0.0**	**0.1**	**-35.5**	**0.2**	**-35.3**
Capital increase	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital increase exercised options	0.0	0.1	0.0	0.0	-0.1	0.0	0.0	0.0	0.0
Share-based payment charge for the period	0.0	0.0	0.0	0.0	2.0	0.0	2.0	0.0	2.0
Issuance of convertible bonds	0.0	0.0	0.0	-23.4	0.0	0.0	-23.4	0.0	-23.4
Repurchase of convertible bonds	0.0	0.0	7.5	-0.1	0.0	0.0	7.4	0.0	7.4
Balance as at 31 December 2025	**0.4**	**755.5**	**-358.2**	**36.9**	**24.0**	**0.6**	**459.2**	**20.0**	**479.2**
Comprehensive income for the period									
Loss for the period	0.0	0.0	-5.8	0.0	0.0	0.0	-5.8	-1.1	-6.9
Other comprehensive income for the period	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2
Total comprehensive income for the period	**0.0**	**0.0**	**-5.8**	**0.0**	**0.0**	**0.1**	**-5.7**	**-1.0**	**-6.7**
Capital increase	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital increase exercised options	0.0	3.3	0.0	0.0	-0.9	0.0	2.4	0.0	2.4
Share-based payment charge for the period	0.0	0.0	0.0	0.0	1.4	0.0	1.4	0.0	1.4
Dividend paid to non-controlling interests	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.2	-1.2
Movement as result of expired options	0.0	0.0	2.5	0.0	-2.5	0.0	0.0	0.0	0.0
Balance as at 30 June 2026 (unaudited)	**0.4**	**758.8**	**-361.5**	**36.9**	**22.0**	**0.7**	**457.3**	**17.8**	**475.1**

Notes to the consolidated interim financial statements.

1. General information / summary of material accounting policies.

Redcare Pharmacy N.V. is a limited liability company incorporated in the Netherlands and legally domiciled in Sevenum, the Netherlands, with its registered address at Erik de Rodeweg 11/13, 5975 WD Sevenum. Redcare Pharmacy N.V. is listed on the regulated market of the Frankfurt Stock Exchange. The Company is registered with the Dutch Commercial Register under number 63986981.

The consolidated financial statements include the Company and all its subsidiaries (jointly referred to as "Redcare"). The financial year of the Group is equal to the calendar year.

The consolidated half-year financial statements for the first six months ending 30 June 2026 were authorised for issuance by the Managing Board on 28 July 2026, and have not been audited or reviewed by an external auditor.

Basis of preparation of half-year report.

The consolidated interim financial statements for the six-month period ended 30 June 2026 have been prepared in accordance with Accounting Standard IAS 34 "Interim Financial Reporting", as adopted by the European Union, and therefore do not include all the information and disclosures as required in an Annual Report based on EU-IFRS. Accordingly, these financial statements are to be read in conjunction with the Annual Report 2025 and any public announcements made by Redcare Pharmacy N.V. during the interim reporting period.

The accounting policies adopted are consistent with those of the corresponding, previous financial year end interim reporting period. The consolidated financial statements for 2026 have been prepared in accordance with IFRS Accounting Standards as adopted by the International Accounting Standards Board (IASB), as endorsed by the EU in accordance with Dutch Civil Code, Book 2, Title 9.

Change in presentation currency unit.

From year end 2025, the Group presents its financial information in EUR millions rather than EUR thousands to enhance clarity and readability. Comparative figures for the six-month period ended 30 June 2025 have been restated accordingly by dividing previously reported amounts by 1,000 and rounding to the nearest EUR million. This change affects presentation only and has no impact on the Group's financial position, performance or cash flows.

Use of estimates and judgements.

The preparation of interim consolidated financial statements in compliance with IAS 34 requires the use of certain critical accounting estimates. It also requires Group management to exercise judgement in applying the Group's accounting policies. Estimates and assumptions used in the preparation of the consolidated interim financial statements are considered consistent with those described in the 2026 Annual Report based on EU-IFRS.

2. Going concern.

From 1 January through 30 June 2026, the Company incurred losses after tax of EUR 6.9 million (H1 2025: EUR 2.8 million) and generated a positive cash flow from operating activities of EUR 33.3 million (H1 2025: EUR 70.0 million). The working capital position at 30 June 2026 is a positive EUR 85.5 million (H1 2025: negative EUR 38.9 million).

Based on the Group's period-end cash position (including short-term securities) of EUR 117.6 million, expected operating cash flows and the available committed credit facilities, management expects to have sufficient liquidity to meet ongoing operational and investment requirements.

in millions of Euros	Unaudited 30.06.2026	Unaudited 30.06.2025
Trade and other receivables, prepayments and other current assets	217.8	188.0
Inventory	213.3	161.8
Trade and other payables	-252.2	-245.7
Loans and borrowings (short-term)	-22.8	-77.0
Other liabilities (short-term)	-70.6	-65.9
Working capital	85.5	-38.9
% Revenue	2.66 %	(1.45)%
Working capital incl. cash and short-term securities	203.1	275.8

The Group's liquidity position as at June 30, 2026 primarily reflects the successful refinancing transaction completed in April 2025. On April 16, 2025, Redcare Pharmacy issued EUR 300 million senior unsecured convertible bonds due 2032 with a 1.75% coupon. The proceeds of the new issuance were used to strengthen the capital structure, extend debt maturities, and provide additional long-term financial flexibility.

The Group continuously monitors its liquidity position through short-, mid- and long-term cash flow planning to model future liquidity levels and funding requirements, thereby supporting growth financing and maintaining financial resilience. The underlying unit economics and financial performance in the larger markets are cash-flow positive; however, the Group continues to pursue a fast-growth strategy aimed at expanding market share and increasing its active customer base.

In parallel with this growth focus, the Group is implementing initiatives to improve gross profit margins, enhance other income streams, and drive operational efficiencies and scalability. Management also actively safeguards operational flexibility to adjust the balance between growth investment and cash generation as needed. The Group diversifies its funding sources and actively manages financing options to ensure continued financial flexibility.

Based on current forecasts and funding plans, management expects sufficient liquidity to be available for at least the next twelve months from the date of approval of these interim consolidated financial statements. Accordingly, the interim consolidated financial statements have been prepared on a going concern basis.

3. Revenue.

Revenue from type of products and services.

The revenue from type of products and services is the following:

in millions of Euros	Unaudited 30.06.2026	Unaudited 30.06.2025
Rx revenue	655.3	485.6
Non-Rx revenue	1,047.7	940.9
	1,703.0	**1,426.5**

Seasonality of operations.

For the business of Redcare Pharmacy, the first and fourth quarters of the year tend to be slightly higher in sales than the second and third quarters.

Vendor allowances are calculated for the interim financial statements on a pro-rata basis.

4. Segment information.

Our operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision makers. The chief operating decision makers, who are responsible for allocating resources, for assessing performance of the operating segments and for making strategic decisions, have been identified as the statutory members of the Group's Managing Board.

Within the context of IFRS 8, we consider two business segments for external reporting purposes: our DACH segment, which includes medications and pharmacy related BPC (beauty and personal care) products sold to customers in Germany, Austria and Switzerland, and our International segment, which includes OTC (non-prescription) medications and pharmacy-related BPC products sold to customers in Belgium, the Netherlands, France and Italy.

The Group's assets and liabilities are not disclosed by segment as they are not included in the segment information used by the chief operating decision makers. The accounting policies of the operating segments are the same as those described in note 1.

The Group allocates all costs (excluding net finance cost and income tax) to the segments. The result by segment is shown in the EBITDA line including all costs directly related to the revenue of the segments (marketing, operations) and administrative expenses. EBITDA means earnings before tax, interest, depreciation and amortisation.

Revenue and earnings per segment.

non adjusted and adjusted (in millions of Euros)	2026 Unaudited DACH	2026 Unaudited International	2026 Unaudited Total	2025 Unaudited DACH	2025 Unaudited International	2025 Unaudited Total
Revenue	**1,389.1**	**313.9**	**1,703.0**	**1,156.5**	**270.0**	**1,426.5**
Cost of sales	-1,099.0	-237.4	-1,336.4	-890.5	-200.0	-1,090.5
Adjusted cost of sales	*-1,099.0*	*-237.4*	*-1,336.4*	*-890.5*	*-200.0*	*-1,090.5*
Gross profit	290.1	76.5	366.6	266.0	70.0	336.0
Adjusted gross profit	*290.1*	*76.5*	*366.6*	*266.0*	*70.0*	*336.0*
% of revenue	20.9 %	24.4 %	21.5 %	23.0 %	26.0 %	23.6 %
Other income	0.1	0.0	0.1	0.3	0.1	0.4
Adjusted other income	*0.1*	*0.0*	*0.1*	*0.3*	*0.1*	*0.4*
Selling & distribution	-215.2	-64.1	-279.3	-209.6	-60.1	-269.7
Adjusted selling and distribution	*-215.2*	*-64.1*	*-279.3*	*-209.6*	*-60.1*	*-269.7*
Administrative expense	-29.9	-15.0	-44.9	-28.1	-14.3	-42.4
Adjusted administrative expenses	*-29.0*	*-14.4*	*-43.4*	*-26.3*	*-13.2*	*-39.5*
EBITDA	**45.1**	**-2.6**	**42.5**	**28.6**	**-4.3**	**24.3**
Adjusted EBITDA	*46.0*	*-2.0*	*44.0*	*30.4*	*-3.2*	*27.2*
Depreciation	-23.2	-10.7	-33.9	-22.1	-12.0	-34.1
Adjusted depreciation	*-23.2*	*-10.7*	*-33.9*	*-22.1*	*-12.0*	*-34.1*
EBIT	**21.9**	**-13.3**	**8.6**	**6.5**	**-16.3**	**-9.8**
Adjusted EBIT	*22.8*	*-12.7*	*10.1*	*8.3*	*-15.2*	*-6.9*
Net finance cost and income tax			-15.5			7.0
Adjusted net finance cost			*-15.5*			*-7.2*
Net loss			**-6.9**			**-2.8**
Adjusted net loss			*-5.4*			*-14.1*

Adjusted earnings before interest, tax, depreciation and amortisation (adjusted EBITDA).

For better orientation, we also provide adjusted figures, which reflect extraordinary items (the non-cash IFRS specific expenses on accounting of the business acquisitions, the non-cash IFRS expenses related to the Employee Stock Option Plans, and one-off costs related to business projects).

A detailed reconciliation of adjustments can be found in the following table:

in millions of Euros	Adjustments 2026					Adjustments 2025				
	Non-adjusted	**1**	**2**	**3**	**Adjusted**	**Non-adjusted**	**1**	**2**	**3**	**Adjusted**
Revenue	1,703.0	0.0	0.0	0.0	1,703.0	1,426.5	0.0	0.0	0.0	1,426.5
Cost of sales	-1,336.4	0.0	0.0	0.0	-1,336.4	-1,090.5	0.0	0.0	0.0	-1,090.5
Gross profit	366.6	0.0	0.0	0.0	366.6	336.0	0.0	0.0	0.0	336.0
Other income	0.1	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.4
Selling & Distribution	-279.3	0.0	0.0	0.0	-279.3	-269.7	0.0	0.0	0.0	-269.7
Administrative expenses	-44.9	1.4	0.0	0.1	-43.4	-42.4	1.5	1.4	0.0	-39.5
EBITDA	42.5	1.4	0.0	0.1	44.0	24.3	1.5	1.4	0.0	27.2
Depreciation	-33.9	0.0	0.0	0.0	-33.9	-34.1	0.0	0.0	0.0	-34.1
EBIT	8.6	1.4	0.0	0.1	10.1	-9.8	1.5	1.4	0.0	-6.9
Net finance cost	-13.5	0.0	0.0	0.0	-13.5	1.4	0.0	0.0	-14.2	-12.8
Income tax	-2.0	0.0	0.0	0.0	-2.0	5.6	0.0	0.0	0.0	5.6
Net loss	-6.9	1.4	0.0	0.1	-5.4	-2.8	1.5	1.4	-14.2	-14.1

Description of adjustment:
1. IFRS expenses of the Employee Stock Option Plans. Also see note 27 of the 2025 Annual Report. These expenses are non-cash for Redcare Pharmacy.
2. One-off external project expenses related to other projects (for example expansion and acquisition projects). This mainly concerns external advisory costs.
3. Other major non-recurring one-offs. Prior year's number is the effect of repurchasing approximately 70% of the 2021 convertible bonds which resulted in a gain of EUR 14.2 million.

5. Income taxes

Income tax expense is recognised based on management's estimate of the expected annualised income tax rate for the full financial year, as well as discrete items recognised in the first half of the year.

Our effective tax rate for the six-month period ended June 30, 2026 is 41.2% compared to -66.9% for the six-month period ended 30 June 2025. The change in effective tax rate is mainly driven by the 2025 effect of the release of deferred tax liabilities on the repurchased convertible bonds and revision of the estimated future cash flows of the remaining convertible bonds.

6. Earnings per share.

Basic and diluted earnings.

	Unaudited 30.06.2026	Unaudited 30.06.2025
Basic and diluted earnings per share in millions of Euros		
Result for the year attributable to owners of the Company	-5.8	-1.5
Earnings used in the calculation of basic and diluted earnings per share	-5.8	-1.5
Earnings used in the calculation of basic and diluted earnings per share from continuing operations	-5.8	-1.5
Weighted average number of ordinary shares for the purposes of basic and diluted earnings per share	20,117,822	20,111,349
Basic and diluted earnings per share in Euro per share		
From continuing operations	-0.29	-0.07
From discontinued operations	0.00	0.00
Total basic and diluted earnings	-0.29	-0.07

Basic and diluted earnings per share.

The Group has several classes of instruments that could result in the issuance of ordinary shares in the future. The exercise of these instruments depends on the fulfilment of specific conditions, as detailed below. As all such instruments are anti-dilutive for the period ended June 30, 2026, none have been included in the diluted EPS calculation.

Employee stock options.
Assuming full exercise of all outstanding stock options as at June 30, 2026, an additional 684,586 new shares would be exercisable in the future, of which 399,037 have already been issued and are held in treasury.

Convertible bonds.
The Group has issued EUR 300 million 1.75% convertible bonds due 2032 on 16 April 2025. These bonds are convertible into ordinary shares at a fixed conversion price of EUR 173.74 per share. Assuming full conversion of all bonds, a maximum of 1,726,718 new ordinary shares would be issued in the future.

All outstanding bonds and stock options are excluded from diluted EPS because their effect would be anti-dilutive for both continuing and total earnings per share.

The number of outstanding ordinary shares is 20,578,391 as at June 30, 2026. If all potentially issuable shares described above were to be issued, the total number of outstanding shares would increase to 22,590,658.

7. Convertible bond.

The Group has two tranches of convertible bonds outstanding :

• 2021 convertible bonds (due 2028)
In January 2021, the Company issued 2,250 zero-coupon convertible bonds with an aggregate principal amount of EUR 225.0 million. Following the partial repurchase of the convertible bonds in April 2025, bonds with a nominal amount of EUR 67.1 million remained outstanding as at December 31, 2025.

Bondholders of the 2021/2028 convertible bonds, exercised their rights pursuant to the terms and conditions of the Convertible Bond to redeem EUR 64.5 million of the bonds on January 21, 2026.

The EUR 64.5 million redemption was effected by January 21, 2026. It reduced Redcare's outstanding current liabilities under the Convertible Bond. As a result of the completion of this transaction, the remaining nominal amount of the 2021/2028 bonds amounts to EUR 2.6 million.

• 2025 convertible bonds (due 2032)
On April 16, 2025, the Company issued EUR 300 million senior unsecured convertible bonds bearing 1.75% annual interest, payable semi-annually, and maturing on April 16, 2032. Each bond is convertible into ordinary shares at a conversion price of EUR 173.74 per share. Bondholders may exercise a put option on April 16, 2030 to redeem the bonds at the accreted redemption amount plus accrued interest.

The convertible bonds are accounted for as a compound financial instrument and have been separated into a liability component and an equity component at initial recognition.

The effective interest rate of the liability component on initial recognition is 5.16% per annum.

Movements of the convertible bonds.

A summary of the movements of the convertible bonds is given below:

in millions of Euros	Issued on 14.01.2021	Issued on 08.04.2025	Total
Balance 1 January 2026	66.8	266.5	333.3
Interest charged calculated at an effective interest rate	0.3	7.0	7.3
Interest paid	0.0	-2.6	-2.6
Redemption of convertible bonds	-64.5	0.0	-64.5
Balance 30 June 2026	**2.6**	**270.9**	**273.5**

Current versus non-current

in millions of Euros	Unaudited 30.06.2026	31.12.2025
Liability component	273.5	333.3
of which long-term position	266.3	261.9
of which short-term position	7.2	71.4

8. Fair value.

The Company considers that the carrying amounts of financial assets and financial liabilities recognised in the consolidated financial statements approximate their fair values, except for the convertible bond which is presented as part of the non-current and current loans and borrowings, accounted for based on amortised costs.

For the six-month period ended 30 June 2026, no significant changes of fair value calculations have occurred in comparison to the fair values from the 2025 Annual Report.

9. Commitments, contingencies and guarantees.

The nature, scale and scope of commitments, contingencies and guarantees are in line with those disclosed in the 2025 Annual Report.

10. Subsequent events.

There have been no significant subsequent events.

11. Signing of the financial statements.

Sevenum, the Netherlands, 28 July 2026

Redcare Pharmacy N.V.
The Managing Board:

Olaf Heinrich Hendrik Krampe Theresa Holler Lode Fastré

Definitions.



Active customers
Unique customers who have placed at least one order in the 12 preceding months, predominantly via our online shops, for both our own-stock and platform business. Business-to-business (B2B) orders are excluded to not distort visibility on relevant trends. Platform-only customers are not yet included.

Administrative expenses
Cost of corporate overhead of which examples are IT services, Finance, HR, Facility, Legal and Executive Management.

Adjusted EBITDA
Earnings Before Interest, Tax, Depreciation and Amortization excluding Adjustments. We use this metric as we find it an important indicator of our underlying operational financial performance.

Adjustments
Items we adjust to get from EBITDA to Adjusted EBITDA. There are three categories: (a) Expenses of the employee stock option programs, (b) Non-recurring or extraordinary expenses related to projects, (c) Any other major non-recurring (one-off) items of which we would release what it concerns in case we record it as specifically mentioned.

(Adjusted) EBITDA margin
(Adjusted) EBITDA as a percentage of sales.

Average shopping basket
The average gross value of received orders from end-customers and patients (B2C), predominantly via our online shops for our own-stock business, divided by the total related number of orders placed in a given time period. Current prescription medication sales (Rx) in Switzerland and the Netherlands are not included because we believe current non-comparable customer types would distort visibility on relevant trends in this metric. Business-to-business (B2B) order share excluded for the same reason. The average shopping basket includes value-added tax (VAT).

BPC products
Beauty and personal care products.

CAGR
Compound annual growth rate

DACH segment
Segment reporting provides financial information about the individual units of the company. Redcare uses a regional approach. The DACH Segment comprises its business activities in Germany, Austria and Switzerland.

EBIT
Earnings Before Interest and Tax.

e-RX / e-script
Computer-based electronic generation, transmission, and filling of a medical prescription.

Group
Redcare Pharmacy N.V., Sevenum, the Netherlands, together with its consolidated subsidiaries.

International segment
Segment reporting provides financial information about the individual units of the company. Redcare uses a regional approach. The International Segment comprises its business activities in France, Italy, Belgium and the Netherlands.

Mobile visits
Site visits to our online shops originating from computers, tablets and smartphones as well as other computer-based means.

Net working capital
The difference between the company's current assets (including: trade and other receivables and inventories) and its current liabilities (including: trade and other payables, short-term loans and borrowing and short-term other liabilities).



NPS
Net promoter score of our B2C own stock and platform business for a given period of time. NPS does not yet include MedApp, GoPuls and MediService. We track NPS as an indicator for customer satisfaction.

Number of orders
Number of end-customer and patient (B2C) orders, predominantly placed via our online shops for both our own-stock and platform business, containing at least one product, placed during the measurement period.

OTC products or medications
Products or medicines sold to a customer without a prescription from a healthcare professional, as compared to prescription- only medicines, which may be sold only to customers possessing a valid prescription.

Pharmacy-related products
Products that are almost exclusively distributed through pharmacies.

Private labels or own brands
By private labels (or own brands) we mean the brands of products owned by Redcare Pharmacy or its subsidiaries.

Return rate
Percentage of billed B2C orders for our own stock business that incorporated a return or reclamation of total billed orders in a given time period. Current prescription medication sales (Rx) in Switzerland and the Netherlands are not included because we believe the current non-comparable customer types would distort visibility on relevant trends in this metric. Business-to-business (B2B) orders are excluded for the same reason.

Rx products or medications
Prescription-only medicines, which are only allowed to be sold to customers possessing a valid prescription.

Rx revenues
Sales related to prescriptions of our own stock business in the DACH Segment.

Sales
Gross revenues minus value added taxes and discounts.

Selling and distribution expenses
Expenses related to marketing, shipping, packaging, payments and operational labour to support our Sales.

Share of mobile visits
Mobile visits as a percentage of site visits.

Share of repeat orders
Percentage of total orders, predominantly related to our online shops for both our own-stock and platform business, that is billed during the measurement period that is not the initial order bill to the customer. Business-to-business (B2B) orders are excluded to not distort visibility on relevant trends; with this definition we aim to provide the most relevant insight as to the development of this metric. The share of repeat orders related to platform-only customers is not yet included.

Website visits (Web Traffic)
Unique interactions of a visitor on our website (online shops); a visit is considered terminated when the visitor leaves the browser instance or has not interacted with the page for more than 30 minutes.

Contact.

For the latest full year report, please refer to the Annual Report 2025, which you will find on Redcare Pharmacy's ***Corporate Website*** **https://ir.redcare-pharmacy.com/en** in the Investor Relations section.



Redcare Pharmacy N.V.
Erik de Rodeweg 11/13
5975 WD Sevenum

Media:

Sven Schirmer
Tel: +49 221 99 53 44 31
Email: press@redcare-pharmacy.com

Investor Relations:

Irina Zhurba
Tel.: +31 77 850 6461
Email: investors@redcare-pharmacy.com